Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER THERAPY

Beating cancer one carbon at a time

Subjects

The mitochondrial arm of the one-carbon pathway, which is essential for nucleotide synthesis, becomes dominant in cancer cells due to overexpression of several enzymes of the pathway, including MTHFD2. A study now reports on a high-affinity inhibitor of MTHFD2 that starves cancer cells of DNA building blocks and shows potential for selective tumor targeting.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Targeting the 1C pathway in cancer.

References

  1. Niederhuber, J.E., Armitage, J.O., Doroshow, J.H., Kastan, M.B. & Tepper, J.E. Abeloff’s Clinical Oncology 6th edn. (Elsevier, 2020).

  2. Zhao, L. N. et al. Oncogene 40, 2339–2354 (2021).

    Article  CAS  PubMed  Google Scholar 

  3. Ducker, G. S. & Rabinowitz, J. D. Cell Metab. 25, 27–42 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Nilsson, R. et al. Nat. Commun. 5, 3128 (2014).

    Article  PubMed  Google Scholar 

  5. Bonagas, N. et al. Nat. Can. https://doi.org/10.1038/s43018-022-00331-y (2022).

    Article  Google Scholar 

  6. Ducker, G. S. et al. Cell Metab. 23, 1140–1153 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Temple, C. Jr et al. J. Med. Chem. 25, 161–166 (1982).

    Article  CAS  PubMed  Google Scholar 

  8. Tonkinson, J. L. et al. J. Pharmacol. Exp. Ther. 287, 315–321 (1998).

    CAS  PubMed  Google Scholar 

  9. Schmidt, A. et al. Biochemistry 39, 6325–6335 (2000).

    Article  CAS  PubMed  Google Scholar 

  10. Eadsforth, T. C., Maluf, F. V. & Hunter, W. N. FEBS J. 279, 4350–4360 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gustafsson, R. et al. Cancer Res. 77, 937–948 (2017).

    Article  CAS  PubMed  Google Scholar 

  12. Ju, H. Q. et al. J. Natl. Cancer Inst. 111, 584–596 (2019).

    Article  PubMed  Google Scholar 

  13. Pikman, Y. et al. J. Exp. Med. 213, 1285–1306 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kawai, J. et al. J. Med. Chem. 62, 10204–10220 (2019).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thanos D. Halazonetis.

Ethics declarations

Competing interests

T.D.H. is the chief scientific officer of FoRx Therapeutics, a company that develops drugs for the treatment of cancer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dionellis, V.S., Halazonetis, T.D. Beating cancer one carbon at a time. Nat Cancer 3, 141–142 (2022). https://doi.org/10.1038/s43018-022-00333-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00333-w

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer